6 recruiting, 2 completed. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 5 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow SCLC, Limited Stage: new trials by email Literature Review of SCLC, Limited Stage trials Research Report on SCLC, Limited Stage
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy CCRT(Employed residual field irradiation(RFI)), CCRT(Involved-Field Radiotherapy (IFRT)) - SCLC, Limited Stage | Phase 2 | Recruiting | Henan Cancer Hospital | 200 | 2026-07-17 | 2026-07-21 |
| A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC Tislelizumab + Anlotinib - SCLC, Limited Stage | Phase 2 | Recruiting | Yantai Yuhuangding Hospital | 20 | 2025-11-04 | 2026-09-11 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT SCLC, Limited Stage | Completed | The First Affiliated Hospital with Nanjing Medical University | 25 | 2025-07-08 | 2026-10-20 | |
| Omitting CTV for Primary Tumor in LS-SCLC Radiation Therapy, Etoposide + carboplatin; Etoposide + cisplatin, Creating CTV for primary tumor - SCLC, Limited Stage, Radiation Exposure | Phase 3 | Recruiting | Sun Yat-sen University | 852 | 2025-06-03 | 2025-06-06 |
| Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin - SCLC, Limited Stage | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 45 | 2024-05-22 | 2025-04-04 |
| Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) Durvalumab, Chemotherapy drug of EP regimen, radiotherapy - SCLC, Limited Stage | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 58 | 2023-06-01 | 2024-06-17 |
| Lung Cancer Registry Lung Cancer, NSCLC Stage IV | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 290 | 2020-08-18 | 2026-10-16 |
Carcinoma, Non-Small-Cell Lung (1) · Disease (1) · Disease Progression (1) · Lung Neoplasms (1) · Radiation Injuries (1) · Small Cell Lung Carcinoma (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Disease Attributes (1) · Lung Neoplasms (1) · Wounds and Injuries (1)
Carboplatin (2) · Cisplatin (2) · Etoposide (2) · Radiotherapy (2) · Surgical Procedures, Operative (1) · anlotinib (1) · durvalumab (1) · tislelizumab (1)
Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Guangdong Provincial People's Hospital (1) · Hebei Medical University Fourth Hospital (1) · Henan Cancer Hospital (1) · Peking University First Hospital (1) · Sun Yat-sen University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Yantai Yuhuangding Hospital (1)
China (7) · Austria (1)
Richard Greil, MD (1) · Wenbin Shen, PhD (1)